Mr. Hugh Rogers reports

BIONXT SOLUTIONS INC. ANNOUNCES EXTENSION OF CONVERTIBLE DEBENTURES AND ISSUANCE OF WARRANTS

Bionxt Solutions Inc. has amended the terms of previously issued unsecured convertible debentures in the principal amounts of $425,000, $285,000, $1.4-million, $865,000, $1.6-million and $900,000, bearing interest at a rate of 8 per cent per annum, and maturing on Nov. 12, 2026, Nov. 29, 2026, Dec. 19, 2026, Jan. 14, 2027, Feb. 28, 2027, and March 14, 2027, respectively.

The company has amended the debentures to extend the maturity dates of the debentures by one year to Nov. 12, 2027, Nov. 29, 2027, Dec. 19, 2027, Jan. 14, 2028, Feb. 28, 2028, and March 14, 2028, respectively.

As consideration for the agreement of the debentureholders to extend the maturity dates, the company will issue 16.9 million common share purchase warrants of the company to the beneficial holders of the debentures. Each warrant will entitle the holder thereof to purchase one common share of the company at an exercise price of 50 cents per share for a period of 12 months from the date of issuance.

The warrants and any shares issued upon exercise of the warrants and the conversion of the debentures are subject to a statutory hold period of four months plus one day from the date of issuance, in accordance with applicable securities legislation. Completion of the transactions contemplated herein are subject to a number of conditions, including receipt of all necessary regulatory and corporate approvals, including approval from the Canadian Securities Exchange.

For further details regarding the debentures, see the company's news releases dated Nov. 12, 2024, Nov. 29, 2024, Dec. 20, 2024, Jan. 14, 2025, Feb. 28, 2025, and March 14, 2025, copies of which are available under the company's profile on SEDAR+.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems and active pharmaceutical ingredient development. The company's proprietary platforms -- sublingual (thin-film), transdermal (skin patch) and oral (enteric-coated tablets) -- target key therapeutic areas, including autoimmune diseases, neurological disorders and longevity. With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide. Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTCQB Markets under the symbol BNXTF, and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.